Combination therapy of Crohn's disease with an interleukin 12/23 inhibitor and a targeted immunosuppressant: Clinical cases
- Authors: Knyazev O.V.1, Kagramanova A.V.1,2, Lishchinskaia A.A.1, Sabelnikova E.A.1,3, Lazuka N.V.1, Parfenov A.I.1
-
Affiliations:
- Loginov Moscow Clinical Scientific Center
- Research Institute for Healthcare Organization and Medical Management
- Russian University of Medicine
- Issue: Vol 27, No 5 (2025): Gastroenterology
- Pages: 274-278
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/309773
- DOI: https://doi.org/10.26442/20751753.2025.5.203290
- ID: 309773
Cite item
Full Text
Abstract
Several clinical studies, reviews, and clinical observations of dual biological therapy—the simultaneous use of two genetically engineered biological
drugs and/or targeted immunosuppressants in Crohn's disease (CD)—have been published in recent years. The article presents clinical cases with
dual biological therapy with upadacitinib and ustekinumab in patients with severe CD, which was preceded by genetically engineered biological
therapy. After 26 weeks of combination therapy, all patients achieved clinical, endoscopic, and immunobiological remission of CD without serious
adverse events.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Oleg V. Knyazev
Loginov Moscow Clinical Scientific Center
Author for correspondence.
Email: o.knyazev@mknc.ru
ORCID iD: 0000-0001-7250-0977
SPIN-code: 3268-0360
D. Sci. (Med.), Loginov Moscow Clinical Scientific Center
Russian Federation, MoscowAnna V. Kagramanova
Loginov Moscow Clinical Scientific Center; Research Institute for Healthcare Organization and Medical Management
Email: o.knyazev@mknc.ru
ORCID iD: 0000-0002-3818-6205
SPIN-code: 4086-6745
Cand. Sci. (Med.), Loginov Moscow Clinical Scientific Center, Research Institute for Healthcare Organization and Medical Management
Russian Federation, Moscow; MoscowAlbina A. Lishchinskaia
Loginov Moscow Clinical Scientific Center
Email: o.knyazev@mknc.ru
ORCID iD: 0000-0001-7891-2702
SPIN-code: 9369-9674
Cand. Sci. (Med.), Loginov Moscow Clinical Scientific Center
Russian Federation, MoscowElena A. Sabelnikova
Loginov Moscow Clinical Scientific Center; Russian University of Medicine
Email: o.knyazev@mknc.ru
ORCID iD: 0000-0001-7519-2041
SPIN-code: 5387-7552
D. Sci. (Med.)
Russian Federation, Moscow; MoscowNatalia V. Lazuka
Loginov Moscow Clinical Scientific Center
Email: o.knyazev@mknc.ru
ORCID iD: 0009-0006-3851-3305
SPIN-code: 6112-0291
Res. Assist.
Russian Federation, MoscowAsfold I. Parfenov
Loginov Moscow Clinical Scientific Center
Email: o.knyazev@mknc.ru
ORCID iD: 0000-0002-9782-4860
D. Sci. (Med.), Prof.
Russian Federation, MoscowReferences
- Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570-53. doi: 10.1053/j.gastro.2020.12.031
- Haider M, Lashner B. Dual Targeted Therapy for the Management of Inflammatory Bowel Disease. J Clin Gastroenterol. 2021;55(8):661-6. doi: 10.1097/MCG.0000000000001583
- Ahmed W, Galati J, Kumar A, et al. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(3):e361-39. doi: 10.1016/j.cgh.2021.03.034
- Balderramo D. Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease. World J Gastroenterol. 2022;28(47):6743-71. doi: 10.3748/wjg.v28.i47.6743
- Mas EB, Calvo XC. Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients. J Clin Med. 2022;11(4):1076. doi: 10.3390/jcm11041076
- Privitera G, Onali S, Pugliese D, et al. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. J Crohns Colitis. 2020;jjaa149. doi: 10.1093/ecco-jcc/jjaa149
- Glassner K, Oglat A, Duran A, et al. The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study. J Dig Dis. 2020;21(5):264-71. doi: 10.1111/1751-2980.12867
- Kwapisz L, Raffals LE, Bruining DH, et al. Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. Clin Gastroenterol Hepatol. 2021;19(3):616-1. doi: 10.1016/j.cgh.2020.02.017
- Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007;13(1):2-11. doi: 10.1002/ibd.20014
- Yang E, Panaccione N, Whitmire N, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther. 2020;51(11):1031-8. doi: 10.1111/apt.15719
- Honap S, Netter P, Danese S, Peyrin-Biroulet L. An update on the safety of long-term vedolizumab use in inflammatory bowel disease. Expert Opin Drug Saf. 2023;22(9):767-76. doi: 10.1080/14740338.2023.2247976
- Avedillo-Salas A, Corral-Cativiela S, Fanlo-Villacampa A, Vicente-Romero J. The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate-Severe Crohn's Disease: A Systematic Review. Pharmaceuticals (Basel). 2023;16(11):1581. doi: 10.3390/ph16111581
- Miyatani Y, Choi D, Choi NK, Rubin DT. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease. Dig Dis Sci. 2024;69(2):355-5. doi: 10.1007/s10620-023-08182-y
- Harvey Bradshaw Index for Crohn’s disease calculator. Available at: https://www.thecalculator.co/health/Harvey-Bradshaw-Index-For-Crohn%E2%80%99s-Disease-Calculator-1036.html. Accessed: 25.04.2025.
- Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505-12. doi: 10.1016/s0016-5107(04)01878-4
Supplementary files
